Pulmonary delivery of a p38 α/β MAP kinase inhibitor: bioanalytical method validation and biodistribution in rat plasma and respiratory tissues.

[1]  Shirui Mao,et al.  In vitro-in vivo correlation of inhalable budesonide-loaded large porous particles for sustained treatment regimen of asthma. , 2019, Acta biomaterialia.

[2]  F. Acevedo,et al.  Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical Models: Evaluation of the PreciseInhale Technology. , 2017, Journal of aerosol medicine and pulmonary drug delivery.

[3]  E. Gelfand,et al.  Mitogen‐activated protein kinases as therapeutic targets for asthma , 2017, Pharmacology & therapeutics.

[4]  P. Barnes.  Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease , 2016, Pharmacological Reviews.

[5]  Claus-Michael Lehr,et al.  Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD , 2016 .

[6]  P. Colombo,et al.  Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  M. E. Ali,et al.  Pulmonary delivery of anti-inflammatory agents , 2015, Expert opinion on drug delivery.

[8]  P. Norman.  Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease , 2015, Expert opinion on investigational drugs.

[9]  R. Panettieri,et al.  p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD. , 2012, Current opinion in pharmacology.

[10]  Mark E Bunnage,et al.  Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. , 2011, Journal of medicinal chemistry.

[11]  K. Chung,et al.  p38 mitogen-activated protein kinase pathways in asthma and COPD. , 2011, Chest.

[12]  M. Bunnage,et al.  Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. , 2010, Journal of medicinal chemistry.

[13]  S. Cryan,et al.  Carrier-based strategies for targeting protein and peptide drugs to the lungs , 2005, The AAPS Journal.

[14]  W. Friess,et al.  How can we bring high drug doses to the lung? , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  Mark Gumbleton,et al.  Challenges in inhaled product development and opportunities for open innovation. , 2011, Advanced drug delivery reviews.

[16]  Peter R. Byron,et al.  Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.